Top

Published in:

01-01-2012 | Symposium on Growth Hormone

Biosimilar Growth Hormone

Author: Paul Saenger

Published in: Indian Journal of Pediatrics | Issue 1/2012

Abstract

As the first wave of biopharmaceuticals is expiring, biosimilars or follow-on -protein products (FOPP’s) have emerged. Biosimilar drugs are cheaper than the originator/comparator drug. The regulatory foundation for these products is more advanced and better codified in Europe than in the US. Biosimilar soamtropin has been approved in both the US and Europe. The scientific viability of biosimilar drugs and especially growth hormone has been proven by several rigorously conducted clinical trials. Efficacy and safety data (growth rates, IGF-1 generation) for up to 7 y for pediatric indications measure up favorably to previously approved growth hormones which served as reference comparators. The Obama Administration appears to be committed to establish innovative pathways for the approval of biologics and biosimilars in the US. The cost savings in health care expenditures will be substantial as the global sales of biologics have reached $ 93 billion in 2009.

Dudzinski DM, Kesselheim AS. Scientific and legal viability of follow-on protein drugs. NEJM. 2008;358:843–9.PubMedCrossRef

Kelly CJ, Mir FA. Economics of biological therapies. BMJ. 2009;339:b3276.PubMedCrossRef

Goldman DP, Joyce GF, Lawless G, Crown WH, Willey V. Benefit design and specialty drug use. Health Aff (Millwood). 2006;25:1319–31.CrossRef

Golenski JD. Specialist discretion for managing specialty pharmaceuticals: the ethics argument for discretion. Am J Manag Care. 2004;10:S240–1. discussion 245–51.PubMed

Mullins CD, De Vries AR, Hsu VD, Meng F, Palumbo FB. Variability and growth in spending for outpatient specialty pharmaceuticals. Health Aff (Millwood). 2005;24:1117–27.CrossRef

Glasbrenner K. Technology spurt resolves growth hormone problem, ends shortage. (Medical News). JAMA. 1986;255:581–4. 587.PubMedCrossRef

US. Food and Drug Administration The Orphan Drug Act. www.fda.gov/forindustry/developingproductsforrarediseasesconditions/overview/ucm1194779(accessed Feb 2011).

Maeder T. The orphan drug backlash. Sci Am. 2003;288:80–7.PubMedCrossRef

Brewer GJ. Drug development for orphan diseases in the context of personalized medicine. Trans Res. 2009;154:314–22.CrossRef

10.

Anand G. Lucrative niches: how drugs for rare diseases become lifeline for companies. Wall St J. 2005;15:A1–A18.

11.

Editorial. Regulating a moving frontier. Regulatory Rapporteur. 2009;6:8–9.

12.

European Generic Medicines Association (EGA).Competition and affordability in biopharmaceuticals 2009. http://www/egagenerics.com/ega-biosimilars.htm (accessed Feb 2, 2011)

13.

Pavlovic M, Girardin E, Kapetanovic I, Ho K, Trouvin JH. Similar biological medicinal products containing recombinant human growth hormone. European regulation. Horm Res. 2007;69:14–21.PubMedCrossRef

14.

Complant at 112–122, Sandoz Inc v.Leavitt (D.D.C. 2006), 05-cv-1810 c and Sandoz v Leavitt ,427 F. Supp 2d 29,33 ( D.D.C. 2006 b) , on file with author.

15.

Kozlowski S, Woodcock J, Behrman Sherman R, Midthun K. Developing the nation’s biosimilar program. NEJM. 2011;362:85.

16.

Kessler M, Goldsmith D, Schellekens H. Immunogenicity of biopharmaceuticals. Nephrol Dial Transplant. 2006;21:v0–v12.CrossRef

17.

Louet S. Lessons from Eprex for biogeneric firms. Nat Biotechnol. 2003;21:956–7.PubMedCrossRef

18.

Schneider CK, Kalinke U. Toward biosimilar monoclonal antibodies. Nat Biotechnol. 2008;26:985–90.PubMedCrossRef

19.

McCamish M, Woolett G. Worldwide experience with biosimilar development. MAbs. 2011;3:209–12.PubMedCrossRef

20.

Omnitrope, European Public Assessment Report April 2006, http://www.emea.europaeu/humandocs/Humans/EPAR/omnitrope/omnitrope.htm (accessed Feb 2, 2011).

21.

Valtropin, European Public Assessment Report, April 2006, http://www.emea.europa.eu/humandocs/Humans/EPAR/valtropin/valtropin.htm (accessed Feb 3 2011)

22.

Omnitrope (somatropin) 2006 questions and answers, US Food and Drug Administration, Center for Drug Evaluation and Research, http://www.fda.gov/cder/whatsnew/htm (accessed Feb 3, 2011)

23.

Annex Guideline on Similar Biological Medicinal Products Containing Biotechnology Derived Products as Active Substance: Non-Clinical and Clinical Issues Guidance on Similar Medicinal Products Containing Somatropin, EMES/CHMP/94528/05, CHMP, adopted February 2006

24.

Romer T, Peter F, Saenger P, et al. Efficacy and safety of a new ready to use recombinant human growth hormone solution. J Endocrinol Invest. 2007;30:578–89.PubMed

25.

Romer T, Saenger P, Peter F, et al. Seven years of safety and efficacy of the recombinant human growth hormone Omnitrope in the treatment of human growth hormone deficient children: results of a Phase III study. Horm Res. 2009;72:359–69.PubMedCrossRef

26.

Peterkova V, Arslanoglu E, Bolshova-Zubkovskaya, et al. A randomized double-blind study to assess efficacy and safety of valtropin, a biosimilar growth hormone, in children with growth hormone deficiency. Horm Res. 2007;68:288–93.PubMedCrossRef

27.

Walczak M, Zdavkovic D, Bolshova-Zubkovskaya, et al. A 3 year assessment of the efficacy and safety profile of Valtropin. a recombinant human growth hormone, in children with growth hormone deficiency. Horm Res. 2008;70:97.

28.

Peterkova V, Savoy C, Bezlepkina V, et al. Efficacy and safety of Valtropin in the treatment of short stature in girls with Turner’s syndrome. J Pediatr Endocrinol Metabol. 2004;17:1429–34.CrossRef

29.

Declerck PJ, Darendeliler, Goth M, et al. Biosimilars controversies as illustrated by GH. Curr Med Res Opin. 2010;26:1219–29.PubMedCrossRef

30.

Ranke MB. New preparations comprising recombinant human growth hormone: deliberations on the issue of biosimilars. Horm Res. 2007;69:22–8.PubMedCrossRef

31.

Hoppe W, Berghout A. Biosimilar somatropin: myths and facts. Horm Res. 2007;69:29–30.PubMedCrossRef

32.

Newsletter 2009–130 German Medical Association. Newletter @ akdae.de January 2009.

33.

Sperling MA, Saenger PH, Hintz R, Wilson T, Rose SR. Growth hormone treatment and neoplasia- coincidence or consequence. J Clin Endocrinol Metab. 2002;87:5351–2.PubMedCrossRef

34.

Cuttler L, Silvers JB. Growth hormone and health policy. J Clin Endocrinol Metab. 2010;95:3149–53.PubMedCrossRef

35.

FDA Public Hearing on Approval Pathway for Biosimilars and Interchangeable Biological Products. 11/3/2010 Transcript Document ID: FDA −2010—N 0477-012.www.regulations.govsearch/Regs/home.Html#documentDetail?R=0900006480bafe46.

36.

Federal Register Notice Food and Drug Administration [Docket No FDA-2010 0 N 0477] Approval Pathway for Biosimilar and Interchangeable Biological Products. Public Hearing; Request for Comments http://edocket.access.gpo.gov/2010/pdf2010-24853.pdf.

37.

Biologic Price Competition and Innovations Act (BPCIA) provisions of the Patient Protection and Affordable Care Act (PPACA) http://frebgate.access,gpo.gov/cgi-bin/getdoc.cgi?dbname=111cong.bills&docid=f:3590enr.txt.pdf.

38.

Bell J, Parker KL, Swinford RD, Hoffman AR, Maneatis T, Lippe B. Long- term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab. 2010;95:167–77.PubMedCrossRef

39.

Frank RG. Regulation of follow-on biologics. NEJM. 2007;359:841–3.CrossRef

40.

EMA Press release 2010 http://www.emaeuropaeu/docs/enGB/documentlibrary/Pressrelease/2010/12/WC500099699.pdf

41.

SAGhE http://saghe.aphp.fr/site/spip.php/

Title: Biosimilar Growth Hormone
Author: Paul Saenger
Publication date: 01-01-2012
Publisher: Springer-Verlag
Published in: Indian Journal of Pediatrics / Issue 1/2012
Print ISSN: 0019-5456
Electronic ISSN: 0973-7693
DOI: https://doi.org/10.1007/s12098-011-0610-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Biosimilar Growth Hormone

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2012

Manual of Newborn Care: A. Santhosh Kumar (ed)

Sickle Cell Anemia—Molecular Diagnosis and Prenatal Counseling: SGPGI Experience

Aflatoxin B1 Level in Relation to Child’s Feeding and Growth

Hematidrosis and Hemolacria: A Case Report

History of Growth Hormone Therapy

Magnesium Sulfate Tocolysis and Intraventricular Hemorrhage in Very Preterm Infants